A best evidence topic was written according to a structured protocol. The question addressed was whether the prophylactic administration of somatostatin or somatostatin analogues in patients undergoing pancreaticoduodenectomy (Whipple's procedure) is beneficial in terms of improved surgical outcomes, reduced morbidity or reduced mortality. A total of 118 papers were found using the reported searches of which 5 represented the best evidence (1 meta-analysis, 1 systematic review and 3 randomized control trials). The authors, date, journal, study type, population, main outcome measures and results were tabulated. There is evidence that the perioperative administration of somatostatin or somatostatin analogues reduces biochemical incidence of pancreatic fistula but, it is still unclear if there is a beneficial effect in the incidence of clinically significant pancreatic fistula.
Introduction
A best evidence topic (BET) was structured according to the protocol described previously. 
Clinical problem
In surgical rounds, a patient who has recently undergone a pancreaticoduodenectomy for pancreatic head cancer is presented. The patient had an uneventful post-op course but there is a persistent discharge of an amylase-rich fluid from his drain in postoperative day 10. The patient did not receive prophylactic somatostatin or somatostatin analogues (S/SA). A debate between faculty members is initiated whether the patient should have received prophylactic S/SA and if this treatment is beneficial in patients undergoing Whipple's. You decide to perform a literature search yourself.
Three-part question
In [patients undergoing Whipple's] is [perioperative prophylactic use of S/SA] beneficial [improved post-operative outcomes]?
Search strategy
Search strategy using Medline from 1980 to July 2012 using the PubMed interface: (pancreatic resection OR pancreatic surgery OR pancreaticoduodenectomy OR pancreatico-jejunostomy OR pancreatico-gastrostomy OR Whipple) AND (octreotide OR somatostatin OR somatostatin analogues) AND (outcome OR mortality OR morbidity OR results OR fistula OR collection OR complication OR hospital stay OR length of stay OR cost OR recovery OR intensive care unit stay). Reference lists of key articles were also manually searched for references. Only articles written in English and involving human subjects were included.
Search outcome
One hundred and eighteen articles were retrieved using the above search. Our search retrieved randomized controlled trials (RCTs) and meta-analyses published on this subject in the literature, therefore our selection was shortened to publications providing either level 1 on level 2 evidence (22 articles). From these, 5 studies providing the best evidence to answer the clinical question were identified. Two were systematic reviews published recently (2009 and 2012) and three were randomized controlled trials (RCTs). These are presented in Table 1 .
Results
Three RCTs were included in our BET article. The study by Yeo et al. 3 was the first RCT to address the question by including exclusively patients undergoing a pancreaticoduodenectomy. In total 383 patients were enrolled and randomized. However there was a considerable rate of post-randomization drop-outs in this study (118 patients eventually did not undergo pancreaticoduodenectomy, 14 had a total pancreatectomy and 40 did not receive the minimum of a 5-day course of octreotide), thus allowing a total of 211 patients for analysis. The dosage used was 250 mg of octreotide subcutaneously every eight hours for 7 days.
This study had one of the lowest pancreatic fistula rates ever reported in the literature (9% for the placebo group and 11% for the octreotide group). Surgeons performed either a pancreaticojejunostomy or a pancreatico-gastrostomy and the two groups were comparable with respect to demographics, type of resection, type of anastomosis and final pathologic diagnosis. The overall complication rate was 34% in the control group and 40% in the octreotide group. Complications considered were death, re-operation, pancreatic fistula, wound infection, delayed gastric emptying, intra-abdominal abscess, cardiac arrhythmias, bile leak, pancreatitis, cholangitis, hemobilia and finally, post-operative hospital stay. In contrast to what was published at the time by 4 multicenter European studies, this trial reported no difference in the complication rate between the two groups. Importantly, there was also a subgroup analysis on the impact of octreotide based on the pancreatic texture, i.e. soft, intermediate or hard as defined by the surgeon. There was no difference in complication rate between the subgroups. The authors also reported on the additional economic burden by octreotide administration, estimated as an additional 75$ per patient/per day. This is one of the very few studies in the literature that has actually performed a cost-benefit analysis on the administration of the drug. They finally concluded that the prophylactic perioperative use of octreotide is not reducing the incidence of pancreatic fistula, the overall complications, the mortality or the length of hospital stay and, that the prophylactic use of octreotide should be eliminated at a considerable cost savings. Gouillat et al. 4 assessed the effects of somatostatin -14 (S-14) on pancreatic remnant exocrine secretion following pancreatic surgery. In this RCT patients received a continuous infusion of either S-14 or placebo, for 7 days. A total of 75 were enrolled in this study e all underwent pancreaticoduodenectomy. The pancreatic anastomosis technique was left at the discretion of each surgeon however, the placement of a pancreatic duct tube to facilitate collection of pancreatic juice was mandatory. Additionally, all patients had at least one drain placed in the vicinity of the pancreatic anastomosis. The primary endpoint in this study was reduction in pancreatic juice output. Secondary endpoints were amylase and lipase output and concentration in both the pancreatic juice and the drainage fluid, incidence of clinically evident pancreatic fistula, total pancreatic stump-related complications and length of hospital stay. The authors observed decreased incidence of both clinical pancreatic fistula occurrence (2/38 versus 8/37; p < 0.05) and total stump-related complications (5/38 versus 12/37; p < 0.05) in the study group. The duration of the hospital stay was also lower in the S-14 group (18 versus 26 days; p < 0.01). However, in contrast, there was no difference in the primary endpoint of the study (pancreatic juice output), even though the S-14 group had a lower median output in the first 7 days. The authors concluded that the direct effect of S-14 on the exocrine secretion remains difficult to demonstrate. In a more recent RCT by Kollmar et al., 5 the authors evaluated the impact of octreotide on gastric emptying in patients undergoing pancreaticoduodenectomy. The primary endpoint was the incidence of delayed gastric emptying but, a number of other potential complications following pancreaticoduodenectomy were assessed. Similar to the trial by Yeo et al., 3 the texture of the pancreatic parenchyma was also assessed in this report. Gastric emptying was evaluated by means of a gastric scintigraphy on 7th post-operative day. There were no differences between the two groups in any of the primary or secondary endpoints. The authors concluded that prophylactic administration of octreotide in patients undergoing pancreaticoduodenectomy should be avoided.
Lai et al. 6 published a systematic review on measures to prevent pancreatic fistula following pancreaticoduodenectomy that preceded the most recent meta-analyses by Gurusamy et al. 7 by three years. This systematic review included the above RCTs except the one reported by Kollmar et al. 5 which was not published at the time of data search. The review concludes that the use of octreotide to prevent pancreatic fistula remains controversial but there is strong evidence that octreotide does not reduce mortality. The available evidence qualifies as level 1 and 2. The identified reasons for these findings were poor pooling of data from RCTs and heterogeneity of the available studies for endpoint measures, definition of outcome measures, treatment regimes, pathologic findings, types of pancreatic surgery and anastomotic technique. Most recently, Gurusamy et al. 7 published an updated metaanalysis on this subject, including a total of 19 RCTs. In this review, the initial attempt was to evaluate the benefits from the administration of octreotide in both distal and proximal pancreatic surgery and to subsequently perform a subgroup analysis. All the RCTs presented here were part of this analysis and were of the ones that received the highest score in the methodological quality assessment. Out of 19 trials, 17 were classified as having a high risk of bias with the reports by Gouillat et al. 4 and Kollmar et al. 5 being the two with the lowest risk. In total, 2245 patients were analysed. There were no differences in the perioperative mortality or in the number of patients with drug-related adverse effects between the two groups. The overall number of patients with post-operative complications was significantly lower in the S/SA group (RR 0.69; 95% CI 0.58e2.70; N ¼ 687), however there were no differences in re-operation rate or hospital stay. The incidence of pancreatic fistula was lower in the S/SA group (RR 0.63; 95% CI 0.52e0.77; N ¼ 2161), although very few trials reported on the proportion of these fistulas that were clinically significant. In the subgroup analysis of those reporting on clinically significant fistulas, there was no difference between the two groups. The authors concluded that there is need for further adequately powered trials having low risk of bias to address the question of whether the use of prophylactic octreotide is beneficial. Based on the current available evidence S/SA are recommended for routine use in patients undergoing pancreatic surgery. It should be outlined however, that a subgroup analysis on different procedures (i.e. distal pancreatectomy and. pancreaticoduodenectomy) was not performed. This was because there were only two trials (the ones by Gouillat et al. 4 and Kollmar et al. 5 ) that proved to have a low risk of bias in the sensitivity analysis. Therefore, results from this review need to be interpreted with caution when the issue is pancreaticoduodenectomy rather than pancreatic surgery in general.
Clinical bottom line
The administration of S/SA in pancreaticoduodenectomy remains controversial, however it seems from the published literature that a clear benefit is difficult to show. There are very few studies that have approached the issue and have a low risk of bias. Furthermore, there are even fewer studies that have specifically addressed certain subgroups of patients (soft versus hard texture, malignant versus benign disease). Finally it seems that when comparing data from different studies, distal and proximal pancreatic surgery needs to be considered separately. There is a need for further adequately powered, well designed RCTs before definitive conclusions can be drawn. In the meantime, current evidence supports that there is no decrease in the rate of pancreatic fistulas following octreotide administration in pancreaticoduodenectomies and therefore, octreotide should not be administered routinely.
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